MADCAM1 and urinary bladder cancer: Moreover, in four independent cohorts of advanced lung (1/3 of which were treated with Chemo-IO combinations), kidney, and bladder cancer patients, low circulating levels of soluble MAdCAM-1 reflected gut dysbiosis and predicted resistance to PD-1 blockade16.